Tissue Engineering & Bioprinting Patents

Tissue engineering and 3D bioprinting patents cover bioprinting-method and printhead innovations; bioink and biomaterial innovations; vascularization and scaffold innovations; and decellularization, maturation, and organ-manufacturing innovations — with IP held by bioprinting platform companies, biomaterial firms, and regenerative-medicine developers. MAJOR TISSUE-ENGINEERING / BIOPRINTING PATENT HOLDERS: ORGANOVO: 3D bioprinted human tissues (the ExVive liver/kidney tissue models, NovoGen bioprinting), tissue-construct and bioprinting-method IP. BICO / CELLINK: bioprinters (extrusion, inkjet, light-based) and a large bioink portfolio (the leading commercial bioprinting-and-bioink platform, assembled by acquisition). OTHERS: 3D Systems (Allevi bioprinters, regenerative-medicine + United Therapeutics lung partnership), Aspect Biosystems (microfluidic bioprinting), Prellis Biologics (high-resolution holographic bioprinting for vasculature), Volumetric/3D Systems (volumetric bioprinting), United Therapeutics (manufactured organs — bioengineered/xeno lungs), Humacyte (acellular bioengineered human vascular conduit — a regulatory-stage tissue-engineered blood vessel), Vericel (cultured cell therapies), and academic foundational holders (Atala/Wake Forest, Lewis/Harvard embedded printing, Miller/sacrificial vasculature). Bioprinting methods, bioinks, and vascularization are the core tissue-engineering patent domains — and vascularization is the field's binding constraint for thick tissues/organs.

Bioprinting-modality and printhead innovations; bioink composition innovations; crosslinking and biomaterial innovations; and resolution and cell-viability innovations represent core bioprinting patent domains — and the bioink (printable yet cell-supportive) plus the printing method are the two foundational inventions. BIOPRINTING-METHOD PATENTS: extrusion (depositing cell-laden bioink filaments), inkjet/droplet, laser-assisted (LIFT), light-based stereolithography/digital-light-processing DLP, and volumetric (forming a whole construct at once by patterned light in a resin — Volumetric/Prellis), plus embedded/support-bath printing (FRESH — printing soft tissue inside a sacrificial support gel); printhead, nozzle, and multi-material/multi-cell deposition. BIOINK PATENTS: cell-laden hydrogel bioinks — gelatin-methacryloyl GelMA, alginate, collagen, fibrin, hyaluronic acid, PEG-based, and decellularized-extracellular-matrix dECM bioinks; rheology/printability vs. cell-viability balance, sacrificial/fugitive inks (for vasculature), and self-healing/shear-thinning inks. CROSSLINKING / BIOMATERIAL PATENTS: photo/ionic/enzymatic crosslinking for post-print stabilization, mechanical-property tuning, and degradation matched to tissue remodeling. RESOLUTION / VIABILITY PATENTS: high-resolution (cellular/capillary scale) printing, gentle deposition preserving cell viability, and reproducibility. The bioink composition (printable + cell-supportive + biomimetic) and the printing method (especially high-resolution and embedded/volumetric) are the highest-value bioprinting IP.

Vascularization innovations; decellularization/recellularization innovations; scaffold and acellular-graft innovations; and maturation, bioreactor, and organ-scale innovations represent additional tissue-engineering patent domains — and vascularization is the make-or-break problem for any tissue thicker than ~200 µm. VASCULARIZATION PATENTS: creating perfusable vascular networks in printed tissue — sacrificial/fugitive-ink templating (printing a removable network then seeding endothelial cells — Lewis/Miller lineage), embedded printing of channels, microfluidic vascular design, and self-assembled/angiogenic vascularization; overcoming the diffusion limit (cells more than ~200 µm from a vessel die) is the central, valuable problem. DECELLULARIZATION PATENTS: stripping cells from a donor/xeno organ to leave its extracellular-matrix scaffold (preserving native architecture and vasculature), then recellularizing with patient cells (whole-organ engineering — Humacyte's acellular vascular graft is a regulatory-stage example), plus dECM-derived bioinks. SCAFFOLD / ACELLULAR-GRAFT PATENTS: synthetic and natural scaffolds, acellular off-the-shelf grafts (bioengineered blood vessels, patches), and surface functionalization. MATURATION / BIOREACTOR PATENTS: perfusion bioreactors and mechanical/electrical conditioning to mature printed tissue toward function, and organ-scale fabrication and integration. ORGAN-MANUFACTURING PATENTS: whole-organ approaches (United Therapeutics) and immune-compatibility. Vascularization and decellularization/recellularization are the highest-value tissue-engineering IP because they gate the leap from thin tissue models to implantable, organ-scale constructs.

Tissue engineering startup IP strategy must navigate BICO/Cellink's large bioprinter/bioink estate, Organovo bioprinting patents, academic foundational vascularization and bioprinting patents (Wake Forest/Atala, Harvard/Lewis, Rice/Miller — often licensable), Humacyte/United Therapeutics organ-scale patents, broad tissue-engineering and hydrogel prior art, FDA regulatory pathways (tissue products are biologics/devices — a long, decisive gate), and a landscape where vascularization and clinical translation are the binding challenges; understand that generic hydrogels and basic extrusion printing are well-trodden, that the durable IP is in specific bioink compositions, novel printing methods (high-resolution/volumetric/embedded), vascularization, and decellularization/recellularization, and that the regulatory pathway and demonstrated function matter as much as patents; identify whitespace in vascularization, bioinks, high-resolution/volumetric printing, and acellular/off-the-shelf grafts. TISSUE-ENGINEERING STARTUP IP STRATEGY: GENERIC PRINTING/HYDROGELS ARE PRIOR ART — SPECIFIC BIOINKS, METHODS, AND VASCULARIZATION ARE THE IP: patent the specific bioink composition, a novel printing method (high-resolution, volumetric, embedded), and vascularization — not generic extrusion or GelMA; VASCULARIZATION IS THE HIGHEST-VALUE UNSOLVED PROBLEM: perfusable vascular networks that let tissue exceed the ~200 µm diffusion limit are the key to organ-scale constructs — sacrificial templating, embedded channels, and self-assembled vasculature are the most valuable whitespace; DECELLULARIZATION/RECELLULARIZATION AND ACELLULAR GRAFTS ARE A TRANSLATION PATH: stripping/reseeding native scaffolds and off-the-shelf acellular grafts (Humacyte-style) are closer-to-clinic, patentable approaches; BIOINK COMPOSITION IS COMPOSITION-OF-MATTER IP: a novel printable, cell-supportive, biomimetic bioink is durable composition IP; FDA PATHWAY AND DEMONSTRATED FUNCTION ARE PARALLEL MOATS: tissue products face long biologics/device approval — IP without a regulatory and functional-validation plan is incomplete; WHEN TO PATENT: NOVEL BIOINK/METHOD/CONSTRUCT WITH MEASURED PERFORMANCE: file once a system shows measured results (resolution/feature size + cell viability % + vascular perfusion/thickness + tissue function + construct maturity) vs. existing bioprinting/tissue baselines — measured resolution, cell viability, vascularization/perfusable thickness, and tissue function are the critical tissue-engineering IP metrics; KEY FTO CHECKLIST: BICO/Cellink bioprinter + bioink portfolio; Organovo NovoGen bioprinting tissue construct; 3D Systems/Allevi, United Therapeutics organ; Humacyte acellular bioengineered vascular conduit; Prellis/Volumetric volumetric/holographic high-resolution; extrusion/inkjet/LIFT/DLP/embedded-FRESH printing; GelMA/alginate/collagen/dECM bioink, sacrificial/fugitive ink; photo/ionic/enzymatic crosslinking; sacrificial-template/embedded vascularization (Lewis/Miller); decellularization/recellularization; perfusion bioreactor maturation; FDA biologic/device pathway.